Embecta (NASDAQ:EMBC) Updates FY 2026 Earnings Guidance

Key Points

• Embecta raised or reaffirmed FY 2026 EPS guidance at $1.80–$1.90, above the $1.60 analyst consensus, while revenue guidance of approximately $1.0 billion was in line with expectations.
• The stock opened at $3.50, near its 52-week low of $2.77. Analysts maintain a “Reduce” consensus rating, despite an average price target of $11.00.
• Embecta faces continued investor concerns over weak operating performance and pending securities-fraud litigation alleging misleading statements about its insulin pen needle business; several firms cited an August 17, 2026 lead-plaintiff deadline.

Embecta (NASDAQ:EMBC - Get Free Report) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 1.800-1.900 for the period, compared to the consensus estimate of 1.600. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion.

Embecta Price Performance

Shares of NASDAQ:EMBC opened at $3.50 on Friday. The business's fifty day moving average price is $3.32 and its two-hundred day moving average price is $6.67. Embecta has a fifty-two week low of $2.77 and a fifty-two week high of $15.55. The stock has a market capitalization of $207.66 million, a price-to-earnings ratio of 1.84 and a beta of 0.81.

Embecta (NASDAQ:EMBC - Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.29. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Research analysts expect that Embecta will post 1.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Zacks Research upgraded Embecta from a "strong sell" rating to a "hold" rating in a report on Friday, July 17th. Mizuho dropped their price objective on Embecta from $12.00 to $5.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 6th. Bank of America decreased their target price on Embecta from $11.00 to $3.00 and set an "underperform" rating for the company in a research note on Monday, May 18th. Wall Street Zen downgraded Embecta from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 9th. Finally, Weiss Ratings lowered Embecta from a "sell (d+)" rating to a "sell (d)" rating in a research report on Monday. Three equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Embecta presently has a consensus rating of "Reduce" and a consensus target price of $11.00.

Key Stories Impacting Embecta

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Analysts reportedly maintain an average price target of $11.00, substantially above Embecta’s recent trading level, suggesting some analysts see significant recovery potential if the company’s operating and legal issues stabilize. Embecta receives $11 average analyst price target
• Neutral Sentiment: Multiple law firms reminded investors that August 17, 2026 is the deadline to seek appointment as lead plaintiff. The notices concern investors who purchased Embecta securities between November 25, 2025, and May 4, 2026; the deadline itself does not establish wrongdoing or determine the outcome of the case. Kaplan Fox Embecta class action deadline notice
• Negative Sentiment: Several firms publicized a pending securities-fraud class action against Embecta and certain executives, alleging violations of federal securities laws and misleading statements about the insulin pen needle business. The repeated investor alerts may reinforce concerns about governance, disclosure quality, and possible financial liabilities. Hagens Berman Embecta investor alert
• Negative Sentiment: The legal pressure follows a sharp deterioration in Embecta’s operating performance: its latest reported quarterly revenue fell 14.4% year over year, while EPS and revenue both missed analyst expectations. That weak backdrop makes the lawsuit allegations more material to investors and helps explain the stock’s decline.

Hedge Funds Weigh In On Embecta

Hedge funds have recently modified their holdings of the stock. Brooklyn Investment Group grew its position in Embecta by 5.9% during the 4th quarter. Brooklyn Investment Group now owns 19,736 shares of the company's stock worth $234,000 after acquiring an additional 1,098 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Embecta by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company's stock worth $209,000 after purchasing an additional 1,110 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Embecta by 2.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company's stock worth $629,000 after purchasing an additional 1,159 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Embecta by 1.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,271 shares of the company's stock worth $1,785,000 after purchasing an additional 1,520 shares during the last quarter. Finally, Larson Financial Group LLC raised its position in Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company's stock worth $28,000 after purchasing an additional 1,574 shares during the last quarter. Institutional investors own 93.83% of the company's stock.

About Embecta

Embecta Corp NASDAQ: EMBC is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source